Trial Profile

"Efficacy and Safety of Oral/iv Therapy (Cangrelor) in Patients With SCAD Undergoing Complex PCI, the RESPONSE Study"

Status: Not yet recruiting

Phase of Trial: Phase IV

Latest Information Update: 03 Aug 2022

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Cangrelor (Primary) ; Cangrelor (Primary)
Indications Coronary artery disease; Coronary thrombosis; Myocardial infarction
Focus Adverse reactions
Acronyms RESPONSE

Most Recent Events

27 Jul 2022 Planned End Date changed from 1 Jan 2021 to 1 Dec 2023.
27 Jul 2022 Planned primary completion date changed from 1 Jan 2021 to 1 Dec 2023.
27 Jul 2022 Planned initiation date changed from 1 Feb 2020 to 1 Dec 2022.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com